# Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)

> **NCT06158334** · — · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 400 (estimated)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures
- **DRUG:** Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures

## Key facts

- **NCT ID:** NCT06158334
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158334, "Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06158334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*